The Technical Analyst
Sesen Bio Inc [SESN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Sesen Bio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
7.29% $0.629
America/New_York / 7 mar 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 127.96 mill |
| EPS: | -0.100 |
| P/E: | -6.29 |
| Earnings Date: | May 08, 2023 |
| SharesOutstanding: | 203.49 mill |
| Avg Daily Volume: | 1.236 mill |
| RATING 2023-03-07 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -6.29 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.07x |
| Company: PE -6.29 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.593 - 0.665 ( +/- 5.73%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-06 | Kelly Steven | Buy | 600 000 | Stock Option (Right to Buy) |
| 2023-06-06 | Zweifach Sanford S | Buy | 38 700 | Stock Option (Right to Buy) |
| 2023-06-06 | Morris Richard Steven | Buy | 238 000 | Stock Option (Right to Buy) |
| 2023-06-06 | Torok Michael | Buy | 38 700 | Stock Option (Right to Buy) |
| 2023-06-06 | Klichinsky Michael | Buy | 238 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 76.63 |
| Last 87 transactions |
| Buy: 18 644 112 | Sell: 1 508 721 |
Forecast:
01:40 - $0.616
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.629 (7.29% ) |
| Volume | 1.782 mill |
| Avg. Vol. | 1.236 mill |
| % of Avg. Vol | 144.18 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SESN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SESN
Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2023-03-02 11:32:00 - Press Release
Sesen Bio Stockholders Approve Merger With Carisma Therapeutics
Cambridge, mass.--(business wire)--sesen bio, inc. (nasdaq: sesn) (“sesen bio” or the “company”), today announced that its stockholders have voted to approve all proposals, including the pending merger with carisma therapeutics inc. (“carisma”), at the company's special meeting of stockholders (the “special meeting”) held earlier today. dr.
2023-02-28 08:00:00 - Press Release
Sesen Bio Reports Fourth Quarter And Full-year 2022 Financial Results
Cambridge, mass.--(business wire)--sesen bio (nasdaq: sesn) today reported operating results for the fourth quarter and full year ended december 31, 2022, and provided a business update. business update on february 13, 2023, following extensive engagement with sesen bio stockholders, sesen bio and carisma therapeutics, inc. (“carisma”) further amended the previously amended merger agreement announced on december 29, 2022. the terms of the amended merger agreement include: an increase of the one-time special cash dividend expected to be paid to sesen bio stockholders to $75.0 million, or approximately $0.36 per share1. this represents an increase from the expected special cash dividend of approximately $70...
2023-02-21 09:00:00 - Press Release
Leading Independent Proxy Advisory Firm Glass Lewis Joins Iss In Recommending That Sesen Bio Stockholders Vote “for” All Proposals To Approve Pending Merger With Carisma
Cambridge, mass.--(business wire)--sesen bio, inc. (nasdaq: sesn) (“sesen bio” or the “company”), today announced that leading independent proxy advisory firm glass, lewis & co. (“glass lewis”) recommends that stockholders vote “for” all proposals, including the pending merger with carisma therapeutics inc. (“carisma”), in advance of the company’s upcoming special meeting of stockholders (the “special meeting”) scheduled for march 2, 2023. in reaching its conclusion that stockholders should support all proposals, including the merger and the proposed reverse stock split, glass lewis noted in its february 17, 2023, report1: "...we believe it is reasonable to conclude that the board has likely secured from carisma the best terms reasonably available to the company at this time...
2023-02-16 16:42:00 - Press Release
Leading Independent Proxy Advisory Firm Iss Recommends Sesen Bio Stockholders Vote “for” All Proposals At March 2 Special Meeting
Cambridge, mass.--(business wire)--sesen bio, inc. (nasdaq: sesn) (“sesen bio” or the “company”), today announced that institutional shareholder services (“iss”) recommends that stockholders vote “for” all proposals, including the pending merger with carisma therapeutics inc. (“carisma”), at the company’s upcoming special meeting of stockholders (the “special meeting”) scheduled for march 2, 2023. iss is widely recognized as a leading independent proxy advisory firm, providing impartial analyses and reports to help investors make informed investment decisions. in reaching its conclusion to support all proposals, including the merger and the proposed reverse stock split, iss noted in its february 16, 2023, report1: “[sesen bio] appears to have conducted a thorough overview of alternatives and is proposing to merge with a well-funded company that has attracted strategic interest from leading biotech companies...
2023-02-16 08:00:00 - Press Release
Sesen Bio To Host Webcast With Carisma Therapeutics To Discuss Pending Merger
Cambridge, mass.--(business wire)--sesen bio, inc. (nasdaq: sesn) today announced that members of its management team will host a fireside chat with members of the carisma therapeutics inc. (“carisma”) management team on tuesday, february 21, 2023, at 8:00 am et. the discussion will cover sesen bio’s pending merger with carisma, as well as carisma’s corporate strategy and clinical programs. sesen bio stockholders can submit questions in advance to ir@sesenbio.com. the webcast, which can be accessed on the events and presentations link on the sesen bio website, will be broadcast live and a replay will be available following the conclusion of the event. as previously announced, sesen bio will hold the special meeting of stockholders via live webcast on march 2, 2023, at 10:00 a...
Latest News
2022-11-30 13:33:11 - Zacks Investment Research
SESEN BIO, INC. (SESN) Upgraded to Buy: What Does It Mean for the Stock?
SESEN BIO, INC. (SESN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
2022-11-22 03:42:38 - 24/7 Wall Street
Bradley Louis Radoff Discloses Activist Position in SESN / Sesen Bio
Fintel reports that Radoff Bradley Louis has filed a 13D form with the SEC disclosing ownership of 6,000,000 shares of Sesen Bio Inc (SESN).
2022-11-07 14:00:22 - PennyStocks
7 Cheap Penny Stocks To Buy For Under $1 Right Now
Penny stocks under $1: Are they worth the risk to buy right now? The post 7 Cheap Penny Stocks To Buy For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-10-21 19:34:46 - Zacks Investment Research
SESEN BIO, INC. (SESN) Flat As Market Gains: What You Should Know
In the latest trading session, SESEN BIO, INC. (SESN) closed at $0.50, marking no change from the previous day.
2022-08-15 10:32:49 - Zacks Investment Research
Best Momentum Stocks to Buy for August 15th
BRT, ERJ, and SESN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 15, 2022.
2022-07-19 13:55:10 - Zacks Investment Research
Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down
Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange for an upfront payment of $40 million.
2022-07-18 10:59:09 - Benzinga
Why Shares Of Sesen Bio Are Down 28% Today
Sesen Bio Inc (NASDAQ: SESN) shares are trading lower by 28.9% at $0.66 Monday morning after the company announced that it has made the decision to voluntarily pause further development in the US of its lead asset, Vicineum. What Happened?
2022-07-18 08:35:05 - Benzinga
Sesen Bio Pauses Clinical Development Of Its Lead Bladder Cancer Candidate In US
Based on a thorough reassessment Sesen Bio Inc (NASDAQ: SESN) has decided to voluntarily pause further development in the U.S. of its lead asset, Vicineum, for non-muscle invasive bladder cancer (NMIBC). The decision was based on a reassessment of the incremental development.
2022-07-10 16:00:00 - PennyStocks
Which Industries Are Penny Stocks Investors Watching Right Now
Use these tips for finding penny stocks in different industries in 2022 The post Which Industries Are Penny Stocks Investors Watching Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-07-08 13:13:19 - Zacks Investment Research
VERU's Shares Jump on Successful COVID-19 Study Results
VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.